Bicycle Therapeutics: Q4 Earnings Insights
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Bicycle Therapeutics Q4 EPS $(0.63) Up From $(0.83) YoY, Sales $3.77M Down From $3.85M YoY
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.63) per share. This is a 24.1 percent increase over losses of $(0.83) per share from the same period last year. The company reported $3.77 million in
Morgan Stanley Initiates Coverage On Bicycle Therapeutics with Equal-Weight Rating, Announces Price Target of $60
Morgan Stanley analyst Jeffrey Hung initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight rating and announces Price Target of $60.
Bicycle Therapeutics Announces Clinical Progress And Updates To Management Team; COO Michael Skynner Appointed To CTO Role
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced continued
Benzinga’s Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades
According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.
Needham Initiates Coverage On Bicycle Therapeutics with Buy Rating, Announces Price Target of $85
Needham analyst Ami Fadia initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Buy rating and announces Price Target of $85.
Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT7480 Program In Journal For ImmunoTherapy Of Cancer
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)